Nathan J Cherrington

List of Publications by Year
in descending order

101	4,657	81900	106344
papers	citations	39 h-index	65 g-index

101	101	101	5192
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Strategies to Diagnose Nonalcoholic Steatohepatitis: A Novel Approach to Take Advantage of Pharmacokinetic Alterations. Drug Metabolism and Disposition, 2022, 50, 492-499.	3.3	5
2	Role of Lung P450 Oxidoreductase in Paraquat-Induced Collagen Deposition in the Lung. Antioxidants, 2022, 11, 219.	5.1	1
3	Response to Comments on â€œRemdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sitesâ€. Molecular Pharmacology, 2022, 101, 121-122.	2.3	1
4	Localization of Xenobiotic Transporters Expressed at the Human Blood-Testis Barrier. Drug Metabolism and Disposition, 2022, 50, 770-780.	3.3	9
5	<scp>PF</scp>â€07321332 (Nirmatrelvir) does not interact with human <scp>ENT1</scp> or <scp>ENT2</scp>: Implications for <scp>COVID</scp>â€19 patients. Clinical and Translational Science, 2022, 15, 1599-1605.	3.1	12
6	Mechanistic Basis of Increased Susceptibility to Nephrotoxicants in Chronic Liver Disease. Current Opinion in Toxicology, 2022, , 100347.	5.0	0
7	Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination. Toxicological Sciences, 2022, 189, 62-72.	3.1	5
8	Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian Modeling. Molecular Pharmacology, 2021, 99, 147-162.	2.3	15
9	ToxPoint: Implications of Species Differences in Function and Localization of Transporters at the Bloodâ€“Testis Barrier. Toxicological Sciences, 2021, 181, 1-2.	3.1	3
10	Multiple Computational Approaches for Predicting Drug Interactions with Human Equilibrative Nucleoside Transporter 1. Drug Metabolism and Disposition, 2021, 49, 479-489.	3.3	9
11	Human Renal Xenobiotic Transporter Expression is Altered in Progression of Nonâ€Alcoholic Fatty Liver Disease as revealed by Quantitative Targeted Proteomics. FASEB Journal, 2021, 35, .	0.5	0
12	Renal Transporter Expression Changes in Rodent Models of Nonalcoholic Steatohepatitis. FASEB Journal, 2021, 35, .	0.5	0
13	Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity. Acta Pharmaceutica Sinica B, 2021, 11, 3869-3878.	12.0	7
14	Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transporters. Pharmacology Research and Perspectives, 2021, 9, e00831.	2.4	4
15	Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. Molecular Pharmacology, 2021, 100, 548-557.	2.3	32
16	Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.. Drug Metabolism and Disposition, 2021, , DMD-MR-2021-000451.	3.3	6
17	Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance. Biochemical Pharmacology, 2020, 174, 113780.	4.4	2
18	Generation of a hTERT-Immortalized Human Sertoli Cell Model to Study Transporter Dynamics at the Blood-Testis Barrier. Pharmaceutics, 2020, 12, 1005.	4.5	10

#	Article	IF	Citations
19	Nucleoside Reverse Transcriptase Inhibitor Interaction with Human Equilibrative Nucleoside Transporters 1 and 2. Drug Metabolism and Disposition, 2020, 48, 603-612.	3.3	15
20	A Two-Way Interaction between Methotrexate and the Gut Microbiota of Male Sprague–Dawley Rats. Journal of Proteome Research, 2020, 19, 3326-3339.	3.7	35
21	Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. Toxicon, 2019, 162, 1-8.	1.6	13
22	Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis. Toxicology and Applied Pharmacology, 2019, 368, 49-54.	2.8	3
23	Cell Model for Studying Nucleoside Transporters, a Key Component of the Blood–Testis Barrier. FASEB Journal, 2019, 33, 507.12.	0.5	1
24	Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology, 2018, 32, e22035.	3.0	11
25	Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. Toxicological Sciences, 2018, 161, 23-33.	3.1	25
26	Gene-by-Environment Interaction of Bcrp^{â^'/â^'} and Methionine- and Choline-Deficient Dietâ€"Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition. Drug Metabolism and Disposition, 2018, 46, 1478-1486.	3.3	6
27	Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis. Toxicological Sciences, 2018, 164, 428-438.	3.1	35
28	Transepithelial transport across the bloodâ€"testis barrier. Reproduction, 2018, 156, R187-R194.	2.6	21
29	Impaired Nâ€linked glycosylation of uptake and efflux transporters in human nonâ€alcoholic fatty liver disease. Liver International, 2017, 37, 1074-1081.	3.9	68
30	Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model. Obesity, 2017, 25, 1069-1076.	3.0	41
31	Localization of nucleoside transporters in rat epididymis. Journal of Biochemical and Molecular Toxicology, 2017, 31, e21911.	3.0	5
32	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharmaceutica Sinica B, 2017, 7, 241-248.	12.0	20
33	Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition, 2017, 45, 1317-1325.	3.3	19
34	In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice. Journal of Biochemical and Molecular Toxicology, 2017, 31, N/A.	3.0	21
35	Dysregulated expression of proteins associated with ER stress, autophagy and apoptosis in tissues from nonalcoholic fatty liver disease. Oncotarget, 2017, 8, 63370-63381.	1.8	68
36	Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir. Biochemical Pharmacology, 2016, 115, 144-151.	4.4	9

#	Article	IF	Citations
37	Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 246-253.	2.5	9
38	Transcription factor binding site enrichment analysis predicts drivers of altered gene expression in nonalcoholic steatohepatitis. Biochemical Pharmacology, 2016, 122, 62-71.	4.4	16
39	Altered Hepatic Transport by Fetal Arsenite Exposure in Dietâ€Induced Fatty Liver Disease. Journal of Biochemical and Molecular Toxicology, 2016, 30, 321-330.	3.0	8
40	Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression. Drug Metabolism and Disposition, 2016, 44, 518-526.	3.3	10
41	Renal Xenobiotic Transporter Expression is Altered in Multiple Experimental Models of Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition, 2015, 43, 266-272.	3.3	15
42	Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes, 2015, 64, 3305-3313.	0.6	29
43	Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 462-470.	2.5	43
44	Altered Regulation of Hepatic Efflux Transporters Disrupts Acetaminophen Disposition in Pediatric Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition, 2015, 43, 829-835.	3.3	55
45	Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. , 2015, 151, 99-106.		18
46	Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids, 2015, 47, 603-615.	2.7	175
47	Identification of a Functional Antioxidant Response Element within the Eighth Intron of the HumanABCC3Gene. Drug Metabolism and Disposition, 2015, 43, 93-99.	3.3	19
48	Systems Level Metabolic Phenotype of Methotrexate Administration in the Context of Non-alcoholic Steatohepatitis in the Rat. Toxicological Sciences, 2014, 142, 105-116.	3.1	17
49	Increased Susceptibility to Methotrexate-Induced Toxicity in Nonalcoholic Steatohepatitis. Toxicological Sciences, 2014, 142, 45-55.	3.1	53
50	Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1209-1219.	3.3	22
51	Organic and inorganic transporters of the testis: A review. Spermatogenesis, 2014, 4, e979653.	0.8	12
52	Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease. Digestive Diseases and Sciences, 2014, 59, 365-374.	2.3	39
53	Localization of Multidrug Resistance-Associated Proteins along the Blood-Testis Barrier in Rat, Macaque, and Human Testis. Drug Metabolism and Disposition, 2014, 42, 89-93.	3.3	24
54	Modeling Human Nonalcoholic Steatohepatitis-Associated Changes in Drug Transporter Expression Using Experimental Rodent Models. Drug Metabolism and Disposition, 2014, 42, 586-595.	3.3	55

#	Article	IF	Citations
55	Selective and Cytokine-Dependent Regulation of Hepatic Transporters and Bile Acid Homeostasis during Infectious Colitis in Mice. Drug Metabolism and Disposition, 2014, 42, 596-602.	3.3	18
56	Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis. Journal of Applied Toxicology, 2014, 34, 726-732.	2.8	40
57	Experimental Nonalcoholic Steatohepatitis Increases Exposure to Simvastatin Hydroxy Acid by Decreasing Hepatic Organic Anion Transporting Polypeptide Expression. Journal of Pharmacology and Experimental Therapeutics, 2014, 348, 452-458.	2.5	39
58	Synergistic interaction between genetics and disease on pravastatin disposition. Journal of Hepatology, 2014, 61, 139-147.	3.7	44
59	Xenobiotic transporter expression along the male genital tract. Reproductive Toxicology, 2014, 47, 1-8.	2.9	8
60	Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicology and Applied Pharmacology, 2013, 268, 132-140.	2.8	153
61	The hepatic bile acid transporters Ntcp and Mrp2 are downregulated in experimental necrotizing enterocolitis. American Journal of Physiology - Renal Physiology, 2013, 304, G48-G56.	3.4	24
62	Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2013, 41, 554-561.	3.3	93
63	Basolateral Uptake of Nucleosides by Sertoli Cells Is Mediated Primarily by Equilibrative Nucleoside Transporter 1. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 121-129.	2.5	27
64	Alcohol Cirrhosis Alters Nuclear Receptor and Drug Transporter Expression in Human Liver. Drug Metabolism and Disposition, 2013, 41, 1148-1155.	3.3	40
65	Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers. Drug Metabolism and Disposition, 2013, 41, 1642-1650.	3.3	43
66	Molecular Mechanism of Altered Ezetimibe Disposition in Nonalcoholic Steatohepatitis. Drug Metabolism and Disposition, 2012, 40, 450-460.	3.3	54
67	Altered Arsenic Disposition in Experimental Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2012, 40, 1817-1824.	3.3	22
68	Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 349-360.	3.3	30
69	Genetic variation in the mouse model of Niemann Pick C1 affects female, as well as male, adiposity, and hepatic bile transporters but has indeterminate effects on caveolae. Gene, 2012, 491, 128-134.	2.2	10
70	Measuring Altered Disposition of Xenobiotics in Experimental Models of Liver Disease. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2012, 52, Unit 23.1..	1.1	2
71	Transporterâ€mediated mechanism of nucleoside penetration of the bloodâ€testis barrier. FASEB Journal, 2012, 26, 1047.7.	0.5	0
72	Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metabolism Reviews, 2011, 43, 317-334.	3.6	136

#	Article	IF	Citations
73	Analysis of Global and Absorption, Distribution, Metabolism, and Elimination Gene Expression in the Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2011, 39, 1954-1960.	3.3	141
74	Variations in ATP-Binding Cassette Transporter Regulation during the Progression of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2011, 39, 2395-2402.	3.3	122
75	Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2010, 38, 2293-2301.	3.3	157
76	Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2009, 37, 2087-2094.	3.3	269
77	Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. European Journal of Pharmacology, 2009, 613, 119-127.	3.5	98
78	Decreased apoptosis during CAR-mediated hepatoprotection against lithocholic acid-induced liver injury in mice. Toxicology Letters, 2009, 188, 38-44.	0.8	15
79	Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Archives of Toxicology, 2008, 82, 959-964.	4.2	50
80	Gender divergent expression of Nqo1 in Sprague Dawley and August Copenhagen x Irish rats. Journal of Biochemical and Molecular Toxicology, 2008, 22, 93-100.	3.0	8
81	Induction of drug metabolism enzymes and transporters by oltipraz in rats. Journal of Biochemical and Molecular Toxicology, 2008, 22, 128-135.	3.0	12
82	Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology, 2008, 250, 82-88.	4.2	86
83	Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicology and Applied Pharmacology, 2008, 226, 74-83.	2.8	134
84	Drug-Metabolizing Enzyme and Transporter Expression in a Mouse Model of Diabetes and Obesity. Molecular Pharmaceutics, 2008, 5, 77-91.	4.6	99
85	Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sciences, 2008, 83, 59-64.	4.3	63
86	Minimal Role of Hepatic Transporters in the Hepatoprotection against LCA-Induced Intrahepatic Cholestasis. Toxicological Sciences, 2008, 102, 196-204.	3.1	20
87	The Nrf2 Activator Oltipraz Also Activates the Constitutive Androstane Receptor. Drug Metabolism and Disposition, 2008, 36, 1716-1721.	3.3	45
88	Induction of Drug-Metabolizing Enzymes by Garlic and Allyl Sulfide Compounds via Activation of Constitutive Androstane Receptor and Nuclear Factor E2-Related Factor 2. Drug Metabolism and Disposition, 2007, 35, 995-1000.	3.3	117
89	Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2007, 35, 1970-1978.	3.3	84
90	Regulation of transporter expression in mouse liver, kidney, and intestine during extrahepatic cholestasis. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 637-647.	2.6	67

#	Article	IF	Citations
91	Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology, 2007, 21, 216-220.	3.0	40
92	Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis. Cell Stress and Chaperones, 2006, 11, 356.	2.9	53
93	Differential Expression of Mouse Hepatic Transporter Genes in Response to Acetaminophen and Carbon Tetrachloride. Toxicological Sciences, 2005, 83, 44-52.	3.1	110
94	XENOBIOTIC AND ENDOBIOTIC TRANSPORTER MRNA EXPRESSION IN THE BLOOD-TESTIS BARRIER. Drug Metabolism and Disposition, 2005, 33, 182-189.	3.3	100
95	DOWN-REGULATION OF MOUSE ORGANIC ANION-TRANSPORTING POLYPEPTIDE 4 (Oatp4; Oatp1b2; Slc21a10) mRNA BY LIPOPOLYSACCHARIDE THROUGH THE TOLL-LIKE RECEPTOR 4 (TLR4). Drug Metabolism and Disposition, 2004, 32, 1265-1271.	3.3	20
96	LIPOPOLYSACCHARIDE-MEDIATED REGULATION OF HEPATIC TRANSPORTER mRNA LEVELS IN RATS. Drug Metabolism and Disposition, 2004, 32, 734-741.	3.3	142
97	INDUCTION OF MULTIDRUG RESISTANCE PROTEIN 3 (MRP3) IN VIVO IS INDEPENDENT OF CONSTITUTIVE ANDROSTANE RECEPTOR. Drug Metabolism and Disposition, 2003, 31, 1315-1319.	3.3	64
98	Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 97-104.	2.5	206
99	Gender-Specific and Developmental Influences on the Expression of Rat Organic Anion Transporters. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 145-151.	2.5	173
100	Tissue Expression, Ontogeny, and Inducibility of Rat Organic Anion Transporting Polypeptide 4. Journal of Pharmacology and Experimental Therapeutics, 2002, 301, 551-560.	2.5	85
101	Tissue Distribution and Chemical Induction of Multiple Drug Resistance Genes in Rats. Drug Metabolism and Disposition, 2002, 30, 838-844.	3.3	138